NAT COMMUN: No. 1 CRISPR technology targets cancer cells in the body. 

Despite the progress we have made in treatment, cancer still kills more than 9 million people worldwide each year.
fact, we still have a lot to learn about the biological behavior of cancer cells and the mechanisms of molecular disease.
In this sense, genome editing provides an unprecedented opportunity to further improve our understanding of cancer biology and promote the development of new preclinical models, as well as more effective and targeted treatment strategies to eliminate cancer cells.
other genetic diseases, cancer development involves multiple genetic mutations, and it is clear that targeting a single gene is often not enough to eliminate cancer cells.
, however, many types of cancer depend on the presence of a single carcinogenic event, which can reprogram cells by removing downstream molecules and (extended) genetic procedures and initiating tumor occurrence.
this is called fusion cancer-causing gene (Fusion oncogenes, FOs), which is a chimed gene that is fused in the box of the encoding sequence of two genes caused by dyed weight rowing.
FOs are common in many cancer types and are a powerful driver of tumor development.
FOs are an attractive therapeutic target because their expression is exclusive to cancer cells and their elimination induces apoptosis in FO-driven cancers.
CRISPR/Cas9-based technology has revolutionized genome editing in mammalian cells and can produce targeted fractures anywhere the genome is needed, opening up new horizons for therapeutic gene editing.
recent pioneering study used HDR repair to insert suicidal genes at specific FO bits in patients with prostate and liver cancer cell line.
this approach is very attractive, it has a very low editorial efficiency (1-10%), limiting the usefulness of this strategy.
recently, based on CRISPR/Cas9 technology, researchers designed a simple, efficient, non-patient-specific gene editing strategy that allows specific and powerful destruction of FO in cancer cells by targeting two inclusions of genes involved in rearm.
as proof of its potential, the researchers further demonstrated that targeting based on transcription factors or tyrosine kinase FO based on the inclusions can reduce tumor burden/mortality in in vivo models.
the FO targeting method proposed here may open up new horizons for selective elimination of cancer cells.
.